Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab
Roshini Claire Anthony, 4 days ago

The CA125* test could be useful at detecting ovarian cancer and various other cancers in the primary care setting, particularly for women aged >50 years, according to a study presented at the recent NCRI** Cancer Conference held in Glasgow, Scotland, UK.

4 days ago
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.

Nerve growth factor tied to overactive bladder symptoms in patients with benign prostatic hyperplasia

12 Sep 2018

An association exists between nerve growth factor and overactive bladder symptoms in patients with benign prostatic hyperplasia, according to a study. Nerve growth factor also correlates with the assessment of successful long-term treatment outcome of bladder outlet obstruction with symptoms of overactive bladder.

This prospective study included 1,778 patients with benign prostatic hyperplasia at Peking University People’s Hospital between January 2011 and January 2013. A commercial enzyme-linked immunosorbent assay kit was used to determine urinary nerve growth factor levels preoperatively.

The investigators determined prostate volume, International Prostate Symptom Score (I-PSS), quality of life, Overactive Bladder Symptom Score (OABSS), ultrasound estimated postvoid residual urine and urodynamics before surgery. I-PSS, OABSS and urinary nerve growth factor levels were evaluated again 1 year after transurethral prostate resection.

Patients with moderate and severe lower urinary tract symptoms had varying urinary nerve growth factor/creatinine levels (mean, 10.513±4.255 vs 12.334±4.048 pg/μmol; p=0.002).

Although no significant difference was seen between patients with grades III/IV and V/VI bladder outlet obstruction (mean, 11.285±4.069 vs 11.781±4.437 pg/μmol; p=0.354), there were significant differences in urinary nerve growth factor/creatinine levels in patients without overactive bladder (mean, 8.132±3.489 pg/μmol), and mild, moderate and severe overactive bladder (mean, 10.128±3.817, 13.232±3.290 and 14.029±3.820 pg/μmol, respectively; p<0.001).

Compared with baseline, mean urinary nerve growth factor/creatinine (8.978±4.022 pg/μmol; p<0.001), and I-PSS and OABSS (10.2±5.4 and 4.3±3.7, respectively; p<0.001 for each) decreased 1 year after transurethral prostate resection.

Moreover, the fair/poor vs the good outcome group had higher mean baseline urinary nerve growth factor/creatinine (12.319±4.017 vs 11.015±4.298 pg/μmol; p=0.045), higher mean 1-year urinary nerve growth factor/creatinine (10.847±4.267 vs 7.850±3.419 pg/μmol; p<0.001) and a lesser mean postoperative change in urinary nerve growth factor/creatinine (1.472±4.928 vs 3.165±4.863 pg/μmol; p=0.031).

Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab
Roshini Claire Anthony, 4 days ago

The CA125* test could be useful at detecting ovarian cancer and various other cancers in the primary care setting, particularly for women aged >50 years, according to a study presented at the recent NCRI** Cancer Conference held in Glasgow, Scotland, UK.

4 days ago
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.